findmyKOL

Joseph Buscema, MD

Basic profile

Tucson Medical Center

ORCIDNone on fileNPI
RegionTucson, AZ · WestSpecialtyGynecologic OncologyFocusOncology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Joseph Buscema is an Oncology physician affiliated with Tucson Medical Center. OpenAlex indexes 96 publications with 5,496 citations (h-index 26).

Overview

Scholarship

indexed output and impact (OpenAlex)
96publications

Distinct works indexed by OpenAlex.

5,496citations

Total citations across indexed works.

26h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    40.1%
    Substance P/Neurokinin-1 Receptor Antagonist32.8%
    Aprepitant100%
    Part B, office-administered25 patients
    Serotonin-3 Receptor Antagonist7.1%
    Palonosetron hcl59%Granisetron hydrochloride40%Ondansetron Odt2%
    Part D + Part B40 patients

    + 3 more classes in this area

  • Cancer & immunology

    25.9%
    Microtubule Inhibitor24.8%
    Paclitaxel100%
    Part B, office-administered16 patients
    Platinum-based Drug0.8%
    Carboplatin100%
    Part B, office-administered16 patients

    + 3 more classes in this area

  • Blood & clotting

    19.6%
    Erythropoiesis-stimulating Agent16.2%
    Darbepoetin alfa100%
    Part B, office-administered11 patients
    Iron, parenteral preparations3.3%
    Ferric derisomaltose100%
    Part B, office-administered11 patients

    + 1 more class in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”